Skip to main content

Table 3 Univariate association analysis of survival

From: Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

 

Non-survivor, N = 53

Survivor, N = 67

p overall

Age 65

0.248

 < 65

37 (69.8%)

54 (80.6%)

 > 65

16 (30.2%)

13 (19.4%)

Sex

1.000

 F

10 (18.9%)

12 (17.9%)

 M

43 (81.1%)

55 (82.1%)

AFP (ng/ml)

36.1 [5.40; 234]

6.20 [3.50; 26.5]

< 0.001

Waiting_time (days)

236 [77.0; 370]

198 [64.5; 316]

0.319

D (mm)

36.8 (20.1)

30.3 (21.1)

0.091

MELD

0.703

 MELD ≤ 15

29 (69.0%)

42 (76.4%)

 MELD = 15–30

9 (21.4%)

8 (14.5%)

 MELD > 30

4 (9.52%)

5 (9.09%)

preTreat

0.319

 No pre-treatment

23 (43.4%)

22 (32.8%)

 Pre-treatment

30 (56.6%)

45 (67.2%)

N

0.109

N = 1

18 (48.6%)

41 (65.1%)

N = 1–3

12 (32.4%)

18 (28.6%)

N > 3

7 (18.9%)

4 (6.35%)

Grade

0.559

 1

8 (32.0%)

15 (44.1%)

 2

15 (60.0%)

18 (52.9%)

 3

2 (8.00%)

1 (2.94%)

Asan

< 0.001

 Exceeding

25 (47.2%)

10 (14.9%)

 Fulfilling

28 (52.8%)

57 (85.1%)

AFP score

0.002

 > 2

18 (40.9%)

8 (13.1%)

 ≤ 2

26 (59.1%)

53 (86.9%)

MC

0.001

 Exceeding

30 (56.6%)

16 (23.9%)

 Fulfilling

23 (43.4%)

51 (76.1%)

UTS

< 0.001

 Exceeding

26 (49.1%)

8 (11.9%)

 Fulfilling

27 (50.9%)

59 (88.1%)

  1. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data
  2. AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria